The American Journal of Medicine
Volume 110, Issue 5 , Pages 352-360 , 1 April 2001

Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia

  • Howard H Knapp, MD, PhD

      Affiliations

    • Lipid Research Clinic (HHK, HS), University of Iowa, Iowa City, Iowa, USA
    • ,
  • Helmut Schrott, MD

      Affiliations

    • Lipid Research Clinic (HHK, HS), University of Iowa, Iowa City, Iowa, USA
    • ,
  • Patrick Ma, MD

      Affiliations

    • Bridgeland Medical (PM), Calgary, Alberta, Canada
    • ,
  • Robert Knopp, MD

      Affiliations

    • Northwest Lipid Research Center (RK), Seattle, Washington, USA
    • ,
  • Bruce Chin, MD

      Affiliations

    • Long Island Jewish Medical Center (BC), Manhasset, New York, New York, USA
    • ,
  • J.Michael Gaziano, MD

      Affiliations

    • VA Boston Healthcare System and Brigham and Women’s Hospital (JMG), Boston, Massachusetts, USA
    • ,
  • Joanne M Donovan, MD, PhD

      Affiliations

    • GelTex Pharmaceuticals, Inc. (JMD, SKB), Waltham, Massachusetts, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Joanne M. Donovan, MD, PhD, GelTex Pharmaceuticals, Inc., 153 Second Avenue, Waltham, Massachusetts 02451
    • ,
  • Steven K Burke, MD

      Affiliations

    • GelTex Pharmaceuticals, Inc. (JMD, SKB), Waltham, Massachusetts, USA
    • ,
  • Michael H Davidson, MD

      Affiliations

    • Chicago Center for Clinical Research (MHD), Chicago, Illinois, USA

Received 17 August 2000 ,Revised 11 December 2000 ,Accepted 11 December 2000.

References 

  1. Lipid Research Clinics Program . The Lipid Research Clinics Coronary Primary Prevention trial results I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351–364
  2. Shepherd J, Cobbe SM, Ford I, et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–1307
  3. AFCAPS/TexCAPS Research Group Downs J, Clearfield M, Weis S, et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998;279:1615–1622
  4. Scandinavian Simvastatin Survival Study Group . Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease (the Scandinavian simvastatin survival study (4S)). Lancet. 1994;344:1383–1389
  5. Cholesterol and Recurrent Events Trial Investigators Sacks FM, Pfeffer MA, Moye LA, et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009
  6. Brown G, Albers JJ, Fisher LD, et al.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289–1298
  7. Blankenhorn DH, Nessim SA, Johnson RL, et al.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233–3240
  8. Post CABG Trial Investigators Campeau L, Hunninghake DB, Knatterud GL, et al.  Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Circulation. 1999;99:3241–3247
  9. National Cholesterol Education Program . Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel II). Circulation. 1994;89:1333–1445
  10. Denke MA. Cholesterol-lowering diets. A review of the evidence. Arch Intern Med. 1995;155:17–26
  11. Hunninghake D, Bakker-Arkema RG, Wigand JP, et al.  Treating to meet NCEP-recommended LDL-C concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract. 1998;47:349–356
  12. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia. Am J Cardiol. 1998;81:582–587
  13. Pasternak RC, Brown LE, Stone PH, et al.  Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and “normal” cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Ann Intern Med. 1996;125:529–540
  14. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease (factors limiting achievement of lipid goals). Am J Med. 1996;100:197–204
  15. Vega G, Grundy S. Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol. JAMA. 1987;257:33–38
  16. Davidson MH, Dillon MA, Gordon B, et al.  Colesevelam hydrochloride (cholestagel) (a new potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects). Arch Intern Med. 1999;159:1893–1900
  17. Braunlin W, Zhorov E, Smisek D, et al.  In vitro comparison of bile acid binding to colesevelam HCl and other bile acid sequestrants. Polymer Preprints. 2000;41:708–709
  18. Holmes-Farley SR, Mandeville WH, Miller KL, et al.  Colesevelam hydrochloride (synthesis and testing of a novel polymer gel pharmaceutical). Polymer Preprints. 2000;41:735–736
  19. Davidson MH, Toth P, Weiss S, et al. Low dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol. In press.
  20. Zocor. In: Physicians’ Desk Reference. Montvale, NJ: Medical Economics; 1999:1921.
  21. Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control–National Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements. Clin Lab Med. 1989;9:105–135
  22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  23. Rifari N, Warnick GR. In: Laboratory Measurement of Lipids, Lipoproteins and Apolipoproteins. Washington, DC: AACC Press; 1994;p. 1–357
  24. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 1995;76:69C–77C
  25. Davidson M, Insull W, Toth P, et al.  Colesevelam, a novel, highly potent, polymeric bile acid sequestrant significantly lowers LDL-C. J Am Coll Cardiol. 2000;35:258A
  26. Davidson M, Hunninghake D, Olson T, et al.  Colesevelam (Welchol), a new, potent, well-tolerated, non-systemic lipid-lowering agent. Atherosclerosis. 2000;151:130
  27. Donovan JM, Stypinski D, Stiles MR, et al. Drug interactions with colesevelam hydrochloride, a novel potent bile acid binding polymer. Cardiovasc Drugs Ther. 2000;14:679–688.
  28. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498–511
  29. Donovan JM, von Bergmann K, Setchell KDR, et al. Effects of colesevelam HCl (WelChol), a novel, potent bile acid-binding polymer on sterol and bile acid metabolism in type IIa hypercholesterolemic subjects. In: van Berge Henegouwen GP, Keppler D, Leuschner U, Paumgartener G, Stiehl A, eds. Bile Acids in Health and Disease. Kluwer Academic Publishers, Dordrecht, 198–204.
  30. Cooper AD. Role of the enterohepatic circulation of bile salts in lipoprotein metabolism. Gastroenterol Clin North Am. 1999;1:211–229
  31. Einarsson K, Ericsson S, Ewerth S, et al.  Bile acid sequestrants (mechanisms of action on bile acid and cholesterol metabolism). Eur J Clin Pharmacol. 1991;40:S53–S58
  32. Shepherd J, Packard CJ, Bicker S, et al.  Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med. 1980;302:1219–1222
  33. Hunninghake DB. HMG CoA reductase inhibitors. Curr Opin Lipidol. 1992;3:22–28
  34. Schectman G, Hiatt J. Dose-response characteristics of cholesterol-lowering drug therapies (implications for treatment). Ann Intern Med. 1996;125:990–1000
  35. Gotto AM, Whitney E, Stein EA, et al.  Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477–484

☆ Funded by GelTex Pharmaceuticals, Inc., Waltham, Massachusetts.

PII: S0002-9343(01)00638-6

The American Journal of Medicine
Volume 110, Issue 5 , Pages 352-360 , 1 April 2001

Article Tools

* Image Usage & Resolution